CLEO DIAGNOSTICS ORD
Cleo Diagnostics Optimises Biomarker Panel for Ovarian Cancer Blood Test Ahead of FDA Submission
Cleo Diagnostics expands ovarian cancer blood test biomarker panel to eight ahead of FDA submission, boosting robustness and paving US market entry (ASX: COV).
Cleo Diagnostics Selects Next-Generation Ella Platform to Deliver Ovarian Cancer Blood Test
Cleo Diagnostics (ASX:COV) selects Bio-Techne's Ella ELISA platform to run its ovarian cancer test, advancing toward FDA 510(k) filing and supply deal.
CLEO Diagnostics Expands US Addressable Market for Pre-Surgical Ovarian Cancer Test
CLEO Diagnostics (ASX: COV) has used an analysis of insurance data to significantly expand the total addressable market in the US for its new pre-surgical ovarian cancer detection test.
Market wrap: late market rally not enough to erase midweek losses
A late rally on Friday wasn’t enough for the Australian share market to recover from ground lost earlier in the week. Despite climbing 0.96% or 73.5 points on Friday, the ASX 200 gave up 0.42% for the week. Inflation still high Australia’s annual consumer inflation rate accelerated to 3.6% in April 2024, its highest level […]
